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Case presentation
A 4-week-old male was admitted to the New England Medical
Center Hospital for evaluation of azotemia and gastroenteritis.
He was delivered at term by Cesarean section to a para 3 gravida
3 mother after a normal pregnancy. The neonatal course was un-
remarkable, but at age 3 weeks he developed loose watery
stools, and his feeding became erratic and his breathing labored.
When admitted to his local hospital, he was dehydrated. The pa-
tient has a healthy 4-year-old sibling with growth parameters at
the 95th percentile. A second sibling who died at age 2 days had
bilateral hydroureters and atrophic kidneys.
Physical examination showed an irritable child with 60 respira-
tions per minute and a blood pressure of 130 mm Hg by flush
technique. Laboratory findings disclosed: BUN, 118 mg/dl;
serum creatinine, 6 mgldl; and T02, 10 mEq/liter. Urinalysis re-
vealed: specific gravity, 1.014; pH, 6.5; and no protein, blood, or
sugar; the urine sediment contained no formed elements.
After intravenous rehydration, neither kidney could be visual-
ized on intravenous pyelogram. Despite the restoration of nor-
mal hydration, the BUN and serum creatinine levels remained
elevated, and peritoneal dialysis was instituted. After dialysis,
another intravenous pyelogram showed poor excretion and con-
centration of dye on the right, and no visualization on the left.
Renal arteriography revealed markedly diminished renal paren-
chyma on the right and no identifiable renal artery or kidney on
the left. Renal function stabilized; the BUN was 50-60 mg/dl and
the serum creatinine was 2.4-3.2 mg/dl. The patient was mon-
itored closely after leaving the hospital and was treated with cal-
cium and sodium bicarbonate supplements.
At age 12 months he was admitted to the Massachusetts Gen-
eral Hospital because of growth arrest and a rising serum creati-
nine concentration; at that time, renal transplantation was first
considered. A cystogram revealed a large bladder with bilateral
vesicoureteral reflux, and bilateral hydroureters. Urethral valves
were demonstrated and fulgurated. A left nephrostomy tube was
inserted but produced no significant urinary drainage. A left
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nephroureterectomy as well as a right ureteral repair, tapering,
and reimplantation were performed. With improved drainage,
antibiotics, dietary manipulation, and supplementation with vita-
min D, calcium, and sodium bicarbonate, the infant slowly began
gaining weight and his bony rickets healed. Over the next 3
months he showed rapid motor development. The BUN stabi-
lized at about 45 mg/dl but the serum creatinine continued to rise,
reaching a level of 4.2 mgldl by the time the patient reached 18
months of age. He had maintained a growth rate parallel to the
third percentile until that time. By age 4.5 years, the patient's
height and weight fell below standard growth curves, and sec-
ondary hyperparathyroidism developed. His bone disease pro-
gressed, and a slipped right femoral epiphysis and a left coxa
vara deformity developed.
Because vascular access proved difficult, peritoneal dialysis
was commenced in preparation for renal transplantation. At age
5 years, renal transplantation was performed using the most ap-
propriate family member, the father, as the donor. Initial immu-
nosuppression consisted of antilymphocyte globulin, predni-
sone, and azathioprine. Severe, acute rejection occurred at 2
weeks but responded to therapy with high-dose prednisone,
azathioprine, actinomycin D, and local x-ray therapy. The BUN
stabilized at 55 mg/dl and the serum creatinine at 1.1 mg/dl; im-
munosuppression was tapered to maintenance levels.
When the patient's condition stabilized, bilateral valgus oste-
otomies of the hips successfully corrected the deformities pro-
duced by his renal rickets. His high blood pressure required con-
trol with hydralazine and hydrochlorothiazide for 6 months. For
2 years, his growth rate was at the fifth percentile, but it slowed
and virtually stopped despite a change to every-other-day predni-
sone therapy (15 mg). The patient's bone age remains 2 years
behind his chronologic age, but his bone disease has healed. Pu-
bescent development is in keeping with bone and height age.
Now 6 years, 4 months after transplantation, the patient's
overall status remains stable. There is no evidence of rejection;
his medications include prednisone, 15 mg on alternate days, and
azathioprine, 50 mg daily. He attends grammar school regularly
with children of his own age.
Discussion
DR. JOHN T. HERRIN (Chief, Pediatric Nephrolo-
gy, Massachusetts General Hospital, and Assistant
Professor of Pediatrics, Harvard Medical School,
Boston, Massachusetts): This patient's disease ii-
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lustrates the typical course of chronic renal failure
in early childhood. His clinical progress demon-
strates the problems posed to the pediatric nephrol-
ogist and, at the same time, presents an opportu-
nity for us to review the changing approaches to pe-
diatric transplantation over the past 10 years.
This patient, born with a congenital anomaly, had
renal insufficiency that was masked by growth until
intercurrent infection increased stress to his already
abnormal kidneys. The normal infant, in an anabol-
ic state, incorporates the primary intracellular con-
stituents protein, potassium, and phosphate into
new cells. In an infant such as this, however, in
whom growth is arrested or in whom an acute cata-
bolic stress occurs, these substances then must be
presented to the kidney for excretion. In this pa-
tient, bicarbonate and salt and water losses in diar-
rhea! stools produced severe acidosis and dehy-
dration, and he developed overt renal failure. Be-
cause the elevated BUN and serum creatinine
levels and the degree of acidosis were more marked
than those usually observed in the dehydration sec-
ondary to diarrhea, an underlying anomaly was sus-
pected and an active investigation was begun.
When a review of the family history furthered our
suspicions of a congenital abnormality, we per-
formed radiologic studies, which demonstrated an
obstructive anomaly with vesicoureteric refiux. Re-
pair of the anatomic defects failed to preserve renal
function, however, and his renal insufficiency slow-
ly progressed until it became complete. This course
is in keeping with the observation that early relief of
obstruction is necessary for a return to normal renal
function Ill].
Kidney transplantation in children, although still
a relatively young clinical procedure, has made
great strides in the past decade. Ten years ago, the
use of renal transplantation and dialysis in children
was limited by technical problems imposed by the
small size of these patients. Advances in therapy
over the last decade, however, have permitted ear-
lier and more successful renal transplantation.
More sophisticated tissue typing and operative
techniques now allow transplantation in children
even as young as 18 to 24 months of age. Good sero-
logic matching, of course, still does not preclude the
possibility of rejection. The patient we are dis-
cussing today, in fact, experienced severe rejection
despite a relatively good match. We now know that
rejection in very young patients manifests itself dif-
ferently than in older patients, and this knowledge
has allowed us to diagnose and treat rejection epi-
sodes earlier. Further, the use of longer courses of
antithymocyte globulin therapy has yielded a de-
crease in the incidence of early, severe rejection.
We also now know that growth arrest can occur
prior to transplantation even in patients with stable
but moderately advanced renal insufficiency and
that "catch-up" or compensatory growth will not
occur following transplantation in such patients.
We have learned that early operative intervention,
before growth arrest occurs, can halt the progres-
sion of bone disease [2-4]. Even the technical prob-
lems that remain with transplantation do not cur-
rently prevent us from performing the operation in
children younger than age 2. In this boy, several
factors contributed to his slow growth even though
his transplant provided for the return of normal re-
nal function. These factors included growth arrest
before his kidney transplant, prior bone disease, de-
mineralization, and a change to alternate-day ste-
roid therapy quite late in the course of his treat-
ment. Even alternate-day therapy, when associated
with bone demineralization, is often associated with
growth retardation [5]. This patient's delayed bone
age and sexual maturation suggest that a greater-
than-normal growth potential still exists. In retro-
spect, therefore, earlier transplantation probably
would have been more beneficial.
Before discussing pediatric renal transplantation
in detail, I would like to examine some of the more
general issues of renal failure in infants. Chronic
renal failure in children less than 5 years of age is
uncommon [2, 6]. The wide variety of patho-
physiologic processes that can cause renal failure in
young children is summarized in Table 1. The major
causes of chronic renal failure in infants are ob-
structive anomalies and vascular accidents. Paren-
chymal anomalies, such as cystic disease, and ac-
quired lesions secondary to sepsis or hemolytic-ure-
mic syndrome increase in frequency with increasing
age. Because an increasing number of infants who
survive intensive treatment for critical neonatal ill-
ness have manifested progressive renal failure, in
the future this group likely will be a major contrib-
utor to the enlarging pediatric transplant pool [6].
One-third of all pediatric patients who require trans-
plantation have renal failure secondary to dysplasia
[2, 6, 7], and many of these infants have bladder or
renal masses that can be palpated during physical
examination.
Because immediate treatment is essential in the
infant with renal failure, evaluation must proceed
concurrently with therapy. One usually suspects
renal failure in the young child because of oliguria
or anuria; partial urinary tract obstruction, how-
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Table 1. Causes of chronic renal failure in young children
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ever, is more often associated with polyuria. A de-
finitive diagnosis of renal failure and estimates of its
severity can be obtained only by measurements of
glomerular filtration rate, such as BUN, serum
creatinine, and creatinine clearance. Before one
assumes that the renal failure is due to intrinsic re-
nal disease, the possibilities of prerenal azotemia
and obstructive uropathy must be eliminated.
A urine sample should be collected as early as
possible in any patient with oliguria or azotemia.
Analysis of urine sediment, urine flow rate, urine-
to-plasma osmolar ratio (Uosm/Pøsm) and fractional
soldium excretion (FENa) are helpful. Diagnostic
values for UOSm/POSm and FENa differ from those in
adults: for infants, a UosmlPosm of less than 1.0 and a
FENa of greater than 3% suggest acute tubular ne-
crosis [7, 8]. Prerenal azotemia often can be ex-
cluded by administering over 1 to 2 hours 20 mllkg
of isotonic or hypotonic saline in fluid containing
dextrose. If oliguria persists, furosemide, 2 to 3 mgI
kg, can be administered. If no response is obtained,
a parenchymal lesion should be suspected, and
closer monitoring of circulatory status, fluid and
electrolyte balance, and acid-base status is war-
ranted.
Ultrasound and radionuclide renal scan should be
used early to define function and exclude significant
upper tract obstruction. Careful bladder catheteri-
zation is mandatory for excluding lower tract ob-
struction. An intravenous line should be placed be-
fore the bladder is catheterized, because a post-
obstructive diuresis can can occur abruptly and be
vigorous [9]. Intravenous pyelography and voiding
cystourethrography also might be necessary for fi-
nal diagnosis. In the presence of defined obstruc-
tion, adequate urinary tract drainage often obviates
the need for immediate dialysis and allows further
diagnostic procedures and metabolic correction to
proceed simultaneously. Continuing metabolic cor-
rection after relief of obstruction often leads to
growth.
When prerenal azotemia and obstructive uropa-
thy have been excluded in a patient with renal fail-
ure, supportive measures should be instituted until
the nature of the intrinsic renal disease has been es-
tablished by x-ray or renal biopsy. Ten years ago,
therapy was only supportive and included adequate
urinary tract drainage, correction of acidosis, and
dietary manipulation to provide sufficient calories,
1.0 to 1.5 glkg protein, suitable potassium and phos-
phate restriction, and administration of phosphate
binding gels, vitamin D, and calcium. The aim was
"metabolic control" until the child was at least 5
years old and was "big enough" to become a candi-
date for dialysis and renal transplantation. At present,
however, if such a patient's renal function deterio-
rates further, as in the patient presented today,
early transplantation should be considered so that
growth arrest and bone disease can be avoided and
symptomatic renal failure can be treated.
Despite early fears that transplantation would
prove too stressful for child and family, numerous
reports over the past 10 years attest to the efficacy
of renal transplantation for end-stage renal failure in
childhood [2-4]. Because few, if any, of the causes
of end-stage renal failure in children are currently
preventable, development of adequate dialysis and
transplantation techniques has been necessary.
Gradual modification of surgical techniques and the
creation of miniature dialysis equipment have pro-
vided treatment for a wider population of pediatric
patients, particularly young infants.
Pediatric transplantation differs significantly from
that in adults, because children comprise a unique
population. These differences have prompted me to
focus on the following specific facets of renal trans-
plantation as it pertains to very young children: (1)
timing of transplantation to protect or preserve
growth; (2) increased prevalence of bone disease
and the necessity of restoring renal function before
significant pathologic changes occur in bone; (3)
special problems of immunosuppression; (4) techni-
cal problems associated with dialysis and transplant
patients of small stature; (5) differences between the
diagnosis of rejection in the very young and in the
adult patient; (6) hypertension after transplantation;
and (7) difficulties in rehabilitation of the pediatric
patient.
Timing of transplant operation. The timing of
transplantation in children is particularly critical be-
cause of its potential impact on the growth of the
patient. The most rapid growth in childhood occurs
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during the first 6 to 12 months of life. Renal failure
or any other chronic illness affecting this early
growth period can lead to subsequent loss of linear
growth. The child undergoing hemodialysis shows
retardation of growth and skeletal development.
Skeletal maturation and fusion of epiphyses can oc-
cur without a corresponding increase in height [10].
This problem is particularly difficult because we
now know that children whose bone age is 12 years
or more at the time of transplantation grow poorly
after operation [2, 11]. Thus, even restoration of
renal function after transplantation and resumption
of normal growth rate can leave a permanent residu-
al growth deficit. The resulting short stature of the
child can become a serious psychologic dis-
advantage. Early transplantation should therefore
be considered if optimal conservative therapy in-
cluding vigorous treatment of osteodystrophy does
not restore growth. If growth is not restored, trans-
plantation is preferable to intensive medical therapy
or parathyroidectomy [3, 4].
Overall, renal transplantation in infants and chil-
dren is as successful as transplantation in adults [2,
3, 12—18]. Of all children who receive transplants,
85% to 95% can be rehabilitated through school or
vocational training [2]. Recent results in the very
young child (1 to 5 years) are the same as in the
older child [3, 12]; more importantly, growth is bet-
ter, and some catch-up growth can occur immedi-
ately after transplantation. As yet, acceptable sur-
vival rates have not been obtained in children less
than one year old.
Bone disease. Children and adolescents with re-
nal failure frequently develop bone disease [19] be-
cause the growing and rapidly remodeling skeleton
is more sensitive to alterations in parathyroid hor-
mone, vitamin D, and its metabolism than is the
adult bony structure [20]. Hyperparathyroidism,
the most common cause of bone disease in children
undergoing dialysis, results in metaphyseal fibrosis
under the growth plate. The resulting interference
with vascular invasion of epiphyseal cartilage and
the development of primary spongiosa can lead to
formation of a bony disc between epiphyseal plate
and metaphysis. This, in turn, leads to growth ar-
rest and a loss of the interlocking connection be-
tween epiphyseal growth plate and metaphyseal
bone [21]. These lesions contribute to slipped
epiphyses and predispose to the development of
genu valgum. Parathyroidectomy or early renal
transplantation should be considered before signifi-
cant damage occurs. Orthopedic procedures (e.g.,
bracing, osteotomy, and pinning) should be coordi-
nated with transplant planning to minimize defor-
mity and maximize healing.
Special problems arising from imnunosuppres-
sion. The major problem in transplantation remains
the suppression of rejection activity without the
production of unacceptable side effects such as
growth suppression, bony demineralization, low-
ered host resistance to infection, and a long-term
risk of malignancy. Children are particularly likely
to be exposed to infection when they return to
school, and their potentially longer life span theo-
retically increases their potential for malignancy.
To minimize the effects of immunotherapy on
growth, measures should be taken to prevent rejec-
tion by optimizing the kidney match and, in less fa-
vorable parent-to-child or cadaver matches, by
modifying antirejection therapy [4].
Selection of a suitable donor for a childhood
transplant recipient follows the same principles
used for donor selection in adult recipients; superi-
or results are obtained in grafts from serologically
defined HLA-identical siblings and well-matched
parent-to-sibling pairs [2]. Nevertheless, some well-
matched and even HLA-identical recipients still ex-
perience severe rejection episodes. The effects of
steroid dosage schedules on growth after trans-
plantation require further review. Growth after
transplantation is influenced by steroid dosage, ade-
quacy of transplant function, and growth potential
(calculated from bone age, stature, and chronologic
age) [22]. It is frequently difficult to determine the
appropriate dose of steroids that will suppress or-
gan rejection without suppressing growth. Too low
a steroid dose can result in rejection and a decrease
in growth because of renal functional deterioration.
Low-dose prednisone, however, (less than 0.2 to
0,3 mg/kg/day) is accompanied by better growth
rates than is higher-dose therapy [14, 15, 17]. Alter-
nate-day steroid treatment appears to be more con-
ducive to restoration of normal growth than is the
daily administration of steroids [23]. Finally, sec-
ond transplants have been successful in children as
they have in adults and, if growth has improved af-
ter the first transplant, higher doses of immuno-
suppressive therapy can be used in the second
transplant.
The use of antithymocyte globulin sometimes al-
lows one to decrease the steroid dosage. By de-
creasing the frequency of early rejection episodes,
we can minimize at least the early steroid toxicity
and infection associated with high-dose immuno-
suppression [4, 24, 25]. At least one study in chil-
dren shows that prolonged administration of rabbit
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antithymocyte serum is associated with prolonged
graft survival and a decrease in morbidity and mor-
tality [4]. The recent report that antithymocyte
globulin given alone can reverse acute rejection
without the need for concurrent intensification of
steroid dosage needs to be evaluated more fully
[26].
Technical problems related to the patient's size.
Over the past decade, new shunt materials have be-
come available, and surgical techniques for creating
access to the patient's circulation for the dialysis
procedure have been improved [27]. Shunts can be
placed proximally in the upper arm or in the groin in
the very small infant (less than 10 kg). Small vessel
size still poses a challenge, particularly where veins
have been used extensively for prior therapy.
Small-diameter grafts are possible, but it is difficult
to maintain their patency. Acceptance of an arterio-
venous fistula and multiple punctures usually is not
possible until the child is 11 or 12 years old or
weighs at least 25 kg. Standard Scribner or modified
Scribner shunts can be used in a child who weighs
between 10 kg and 20 kg. Miniaturized equipment,
such as plate and coil dialysers, and smaller volume
lines have been developed. These mechanical ad-
vances have made hemodialysis practical because
the total extracorporeal volume can be held to less
than 10% of the infant's blood volume. The lower
extracorporeal blood volume reduces the chances
of acute blood shifts to or from the patient and
thereby minimizes the risks of acute hypertension
or pulmonary edema on the one hand, and hypovo-
lemia or shock on the other. Devices currently
available also allow frequent weight monitoring dur-
ing dialysis, and thus allow close control of the pa-
tient's volume status. Finally, controlling the rate of
change in BUN and osmolality by reducing dialyser
efficiency can reduce the risk of disequilibrium syn-
dromes.
Initial concern over placement of an adult-sized
kidney into an infant's abdominal cavity has been
solved by the use of an intraperitoneal or modified
retroperitoneal approach. Adult kidneys have been
used in children weighing more than 10 kg; smaller
recipients require a pediatric donor [3, 28].
Problems in diagnosing rejection in children. The
criteria for allograft rejection differ somewhat in
adults and in young children. First, a small in-
crement in serum creatinine, insignificant in an
adult, can reflect a substantial change in renal func-
tion in a young child. In infants with small muscle
mass, a rise in the serum creatinine of only 0.2 to
0.3 mg/dl should suggest significant rejection [28].
Second, the potentially larger functional reserve of
the adult organ when transplanted into a child
makes the interpretation of the decline in serum
creatinine following transplantation more difficult.
Third, the intraperitoneal positioning of the graft
makes it less accessible to physical examination in
children than in adult transplant recipients. For
these reasons, therefore, one must have a high in-
dex of suspicion of rejection in the pediatric trans-
plant recipient.
Despite these differences, the types of rejection
reactions documented in childhood are similar to
those in adults [28]. Both in the older child and in
the adult, rejection is marked by a sudden decrease
in renal function and by interstitial infiltration of the
graft with lymphocytes and plasma cells. Fever and
graft tenderness usually occur concurrently with a
decreasing urine output, a rise in the BUN and
serum creatinine levels, changes in the urinary sedi-
ment (e.g., lymphocyturia, lymphocyte casts), and
a decrease in urinary sodium excretion. All of these
clinical and chemical features indicate acute rejec-
tion [29]. Confirmation by radionuclide scan, ul-
trasound, intravenous urography, and renal biopsy
is necessary only if the clinical diagnosis of rejec-
tion is doubtful or if the patient does not respond to
therapy relatively rapidly. When the clinical and
chemical changes do not appear simultaneously,
one should consider infection and obstruction, the
two other major diagnostic possibilities [29]. In the
young child, however, particularly one who has re-
ceived an adult allograft, a discrepancy frequently
exists between clinical and chemical evidence for
rejection. Fever is generally present and can be the
only problem for 24 to 72 hours before other evi-
dence of rejection surfaces. In the young child with
an intraperitoneal kidney, signs of intraperitoneal
irritation, bowel dysfunction, and ileus can reflect
rejection. Thus, fever without a definable source,
abdominal signs, and bowel dysfunction should
raise the suspicion of rejection even before the
BUN and serum creatinine levels rise.
Urinary sediment findings can be helpful in ascer-
taining whether rejection is occurring, particularly
in the setting of fever and a minimal change in
serum creatinine levels. Measurements of creati-
nine clearance could provide a more sensitive in-
dication of rejection activity, because the creatinine
clearance often falls before decreases in urine vol-
ume or urine sodium become apparent. Obtain-
ing urine samples at the appropriate times for test-
ing is a difficult problem in small children, espe-
cially so, unfortunately, in the very small infant
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who is often incontinent. Creatinine clearance is
thus of limited use in monitoring the patient's
course after pediatric transplantation.
Further problems in diagnosing rejection occur
when the rejection episode is precipitated by an in-
tercurrent viral or bacterial infection [24, 25]. Chil-
dren are likely to be exposed to viral infections, par-
ticularly when they are rehabilitated early and when
their siblings attend school. Hence, careful obser-
vation is necessary because nonspecific symptoms
and fever are common accompaniments to both re-
jection and viral infection.
Hypertension after transplantation. Hyper-
tension is a frequent complication of the post-
transplant period in children [12—18]. Early hyper-
tension can develop because of fluid and salt reten-
tion, acute tubular necrosis, acute rejection, or
high-dose corticosteroid therapy [12, 15, 30]. Hyper-
tension that occurs later in the child's course can
indicate chronic rejection, generalized vascular ab-
normalities, or, in rare instances, renal artery ste-
nosis [13, 30].
Rehabilitation. The percentage of children and
young adults with kidney transplants who return to
school, college, or vocational training is very high
[2]. The only restrictions on lifestyle in a patient
with a well-functioning renal allograft are exclusion
from contact sports and the necessity of maintain-
ing a constant antirejection regimen, but the general
public's bias that transplant patients cannot return
to full normal activity provides a further obstacle to
rehabilitation. Preparatory discussion between the
health care team and the child's parents, school
guidance counselor, and teachers is necessary if the
patient is to return to full functional potential.
Side-effects of steroid therapy—Cushingoid ap-
pearance, aseptic necrosis, cataracts, diabetes mel-
litus, short stature, and delay in sexual matura-
tion—are significant social stigmata that can com-
plicate rehabilitation and the patient's compliance
with the medical regimen [31]. Although psycho-
social stresses are significant, studies suggest that
the family response correlates better with pre-
morbid family composition and personality traits
than with the nature of the illness or the treatment
modality [31].
Conservative treatment for chronic renal failure
as well as treatment by dialysis or transplantation
place major stresses on a family. The financial
stress alone can be overwhelming. No comparative
cost studies currently are available for treatment of
children, but the total cost of dialysis, including in-
tensive medical regimens, repeated hospitalization,
and recurrent surgical expenses, probably exceeds
the cost of a successful transplant. The results of a
successful transplant, when compared with results
obtained in the treatment of other potentially fatal
illnesses in childhood such as acute leukemia are
superior, especially when measured in terms of
quality of life.
To conclude, (1) kidney transplantation is a rea-
sonable and efficient form of therapy for end-stage
renal failure in children. The likelihood of patient
and graft survival, together with the high rate of re-
habilitation, justify this extensive and expensive
therapy.
(2) A number of features of the pediatric patient
require special attention, particularly growth and
psychosocial stresses. These features influence the
timing of the transplant and selection of a donor,
and they require preparatory guidance to ensure
that the full potential of the recipient is attained.
(3) Technical advances and improved equipment
have expanded the spectrum of pediatric patients
who can benefit from dialysis and subsequent trans-
plantation. These measures have provided a suc-
cessful alternative to death or stunted growth for a
majority of children in the one- to five-year age
range who have renal failure.
(4) In the absence of preventive therapy, we
must continue to work toward improving both dial-
ysis and transplantation therapy, designing mea-
sures that will provide better control of rejection
and normal growth in these patients.
Questions and answers
DR. JOHN T. HARRINGTON: Dr. Grupe, perhaps
you could lead off the question-and-answer period.
DR. WARREN GRUPE (Director of Pediatric Ne-
phrology, Children's Hospital, Boston, Massachu-
setts): For years transplantation has been the pre-
ferred therapy for young patients with end-stage
renal failure. However, as Dr. Herrin discussed,
growth after successful transplantation is variable
and usually impaired. Our studies show that mortal-
ity from chronic hemodialysis is lower than that
from transplantation during the first six months of
therapy and is comparable thereafter [32]. Should
we therefore reassess whether transplantation is the
therapy of choice in all children?
DR. HERRIN: Inhibition of growth remains a ma-
jor problem in children with renal failure, particu-
larly because growth retardation often is already
present when the child develops renal dysfunction.
Treating the problem with dialysis early has become
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accepted therapy in children. As you point out,
some studies show that the 5-year survival is higher
in dialyzed patients than in transplanted patients
[33]. The Los Angeles Children's Hospital group,
who initially used dialysis only as a prelude to trans-
plantation, now consider dialysis long-term thera-
py, particularly in patients who have irreversibly re-
jected their transplanted kidneys and who have re-
current disease [2]. Nevertheless, the change of
lifestyle imposed by chronic hemodialysis in my
opinion drastically limits its application in children
and favors transplantation despite the lack of com-
pensatory growth in older children who have re-
ceived kidney transplants.
DR. JEROME P. KASSIRER: I presume that in some
diseases of children, growth retardation is com-
pletely reversed when the disease is effectively
treated. But in the transplanted patients, normal
growth potential does not seem to be recaptured en-
tirely. What is the difference between these two
groups? Can we blame previous acidosis or meta-
bolic bone disease? Do steroid or immunosuppres-
sive therapies nullify growth potential?
DR. HERRIN: One of the major reasons for the
loss of growth potential might be that renal disease
in children usually is associated with significant
bone disease, as I pointed out earlier [18—20]. In
younger children with renal insufficiency who have
rickets due to vitamin D and phosphate depletion,
appropriate treatment initially leads to compensato-
ry growth, but this growth is not always sustained.
Acidosis, renal osteodystrophy, caloric deficiency,
and endocrine dysfunction, particularly disorders of
somatomedin metabolism and abnormalities of pro-
tein metabolism, all can contribute to growth failure
before transplantation. Glucocorticoid dosage after
transplantation is another factor in growth suppres-
sion. The role of other immunosuppressive drugs
commonly employed is less well defined. The acid-
osis in patients with nonuremic renal tubular acid-
osis can be reversed with treatment, but the contri-
bution to growth failure in patients with chronic
renal failure from retention of hydrogen ions is less
clear.
DR. STEVEN ZELMAN (Renal Fellow, NEMCH):
Does any catch-up growth occur in a young child
who has received a kidney from an identical twin?
DR. HERRIN: I do not have a specific answer.
Most of the transplants between identical twins are
performed in older patients who already have
reached their maximum growth. Legal and ethical
considerations limit transplantation between young
children who are identical twins.
DR. KASSIRER: Does growth rate after trans-
plantation differ between patients receiving daily
versus alternate-day steroid therapy?
DR. HERRIN: Data from the Los Angeles study
show that a change to alternate-day steroids late in
the course produces no compensatory growth [22,
28]. On the other hand, in the Cincinnati series, bet-
ter growth was demonstrated using alternate-day
steroid therapy [23].
DR. GRUPE: The seventh year of life might be a
critical period as far as growth is concerned, al-
though I am not sure why. Twelve of our 110 pediat-
ric transplant patients were less than 7 years old
[34]. Three rejected the allografts before we could
adequately assess their growth. All of the others,
except one with chronic rejection, demonstrated ac-
celerated growth and reached and maintained nor-
mal height for their ages. By contrast, compensato-
ry growth occurred in none of the 76 patients
beyond age 7 who received 98 kidney transplants.
DR. JORDAN J. COHEN: In view of the evidence
that early transplantation is essential if optimal
growth and development is to be restored in young
children with azotemia, it is obviously important
that appropriate cases be identified before the dis-
ease has advanced too far. Do we have good data on
the incidence of chronic renal failure in children,
and do we know whether our present case-finding
techniques are adequate for detecting azotemic
youngsters soon enough?
DR. HERRIN: An unpublished 1970 survey in Cali-
fornia probably provides the best incidence data to
date. Chronic renal failure in children less than 12
months old occurred in fewer than one in 1 million
infants; in children 1 to 16 years old, one in 2 to 3
million; and in the 16- to 18-year age group, one in 1
to 2 million. The incidence, then, is quite low.
Nonetheless, pediatricians should screen for renal
disease in all children with growth failure. Unfortu-
nately, acquired disease leading to growth failure is
more likely to prompt investigation than is con-
genital renal disease, although the latter tends to
produce greater growth retardation.
DR. KASSIRER: With regard to screening for renal
disease, it is important that we understand the rela-
tionship between the prevalence of disease in the
population being "screened" and the significance of
a positive test result. Suppose we carry out a
screening program for renal disease in children with
a test that is 99.9% sensitive and 99.9% specific. If
we screen children from a population in which the
prevalence of renal disease is one in 1 million, posi-
tive test results will occur 1000 times as often in
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normal children as in those with renal disease. If we
use the same test in patients from a population of
children in whom the prevalence of renal disease is
one in 100, however, a positive test will be found 10
times more often in patients with renal disease than
in normal individuals. To judge how effective a
screening program would be in children with growth
failure, therefore, we would need to know the accu-
racy of the proposed test and the fraction of chil-
dren with growth failure who also have renal dis-
ease. Do you have any data or even an estimate of
the fraction of the causes of growth failure in chil-
dren that is attributable to renal failure?
DR. HERRIN: Approximately 1% of children in a
population with short stature have growth retarda-
tion secondary to chronic renal failure [35, 36].
The prevalence of growth retardation in various
reported series of children with chronic renal dis-
ease is 36% to 60% depending on the degree of renal
failure and treatment applied [371.
DR. DAVID BUSHINSKY (Renal Fellow,
NEMCH): The Los Angeles data showing that the
results of second cadaveric transplants are almost
as successful as living, related donor transplants are
very intriguing [2]. What is responsible for the en-
hanced graft survival in the second transplant? Is it
even necessary that the patient receive a kidney
first, or could a skin transplant or blood transfusion
provide the same immunologic advantage?
DR. HERRIN: I can't answer that question direct-
ly. Reactions to the antigens of the transplanted kid-
ney differ in patients receiving a second transplant,
especially if they have been transfused previously. I
do not know of any experiments in children in
which skin transplantation has been used to provide
immunologic enhancement.
DR. HARRINGTON: Dr. Garovoy, do you have any
new information about the impact of blood trans-
fusions?
DR. MARVIN GAROVOY (Director, Tissue Typing
Laboratory, and Nephrolo gist, Renal Division, Pe-
ter Bent Brigham Hospital, Boston, fVtassachu-
setts): At the 8th International Histocompatibility
Workshop in Los Angeles, Opelz presented prelimi-
nary data on approximately 890 patients who had
received cadaver transplants [38]. This study re-
vealed an 80% survival in adult patients who had
received 10 or more units of blood, and a 40% graft
survival in those who had not received any trans-
fusions. At the same workshop, preliminary data
showed an 80% graft survival rate at 6 months in
patients who had received a kidney from a 2 DR
matched donor versus a 55% survival in those who
had had no DR match. An additive effect of DR
matching and blood transfusions, however, was not
observed. If steroids decrease growth after trans-
plantation, and if one wishes to decrease the pa-
tient's need for steroids, either blood transfusions
or DR matching might be especially beneficial in
children. A third approach to decreasing the steroid
dosage is the use of new and different immuno-
suppressive agents. We have initiated a controlled
trial of a new drug, cyclosporin A. Two patients given
no other immunosuppressive agents for 2 to 3
months have been successfully switched from cy-
closporin A to azathioprine without the need for
any steroids. Obviously, much more work needs to
be done before any conclusions can be drawn.
DR. HARRINGTON: Could you comment on the
importance of T-cell monitoring?
DR. GAROVOY: Clearly, T-cell monitoring, an in-
dicator of the efficacy of antilymphocyte globulin,
seems to be important in heart transplantation, in
which the dose of antilymphocyte globulin is adjust-
ed to maintain the total T-cell count under 5% of
baseline [39]. A unique feature about heart trans-
plants is that after about 2 months of an immuno-
suppressive regimen with antilymphocyte globulin,
it has been possible to stop the antilymphocyte
globulin, and many patients have no further rejec-
tion episodes. It is not quite the same story in renal
transplantation in that the value of antilymphocyte
globulin in improving cadaver graft survival has not
yet been clearly established. We now appreciate,
however, that there are at least 3 types of T lympho-
cytes based on functional and morphologic dis-
tinctions: T-helper, T-suppressor, and T-regulator
cells. Perhaps when further information about the
evolution of these subclasses of cells has been
gained, monitoring of specific T-cell subsets will be
of clinical importance.
DR. HARRINGTON: Dr. Herrin, could you expand
on your studies of the use of antithymocyte globulin
alone in the treatment of transplant rejection?
DR. HERRIN: Twenty patients, each of whom re-
ceived a kidney from a living donor, participated in a
prospective randomized study [26]. The patients
initially received azathioprine and steroid treat-
ment. With the onset of acute rejection, the patients
were randomly assigned to a group receiving addi-
tional treatment with either antithymocyte globulin
or a high-dose steroid by "pulse-dose" technique.
Nine of 10 patients in each group have functioning
allografts 14 months after treatment. Of the 9 who
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responded to antithymocyte globulin therapy, 8
have normal renal function. In the steroid-treated
group, renal function is impaired in 3 patients.
DR. HARRINGTON: Was there any difference be-
tween the two groups in the incidence of infectious
complications?
DR. HERRIN: Both groups experienced remark-
ably little problem with infection. One patient in the
steroid-treated group died as a result of a perforated
colonic diverticulum. In the antithymocyte globu-
lin-treated group, 3 significant nonfatal infections
were noted (1 monilial infection and 2 Epstein-Barr
viral infections).
DR. COHEN: Has the administration of growth
hormone or of biologically active vitamin D prepa-
rations been used to stimulate growth in children
with chronic renal failure?
DR. HERRIN: Yes, growth hormone has been
tried. Unfortunately, we do not know the key step
in suppression of growth by steroids. Increasing the
dose of growth hormone can overcome the growth-
suppressing effects of low steroid dosage in animals
[40].
DR. KASSIRER: What is known about trans-
plantation in metabolic disorders of the kidney,
such as oxalosis and cystinosis?
DR. HERRIN: We have some information about
transplantation in patients with oxalosis, cystinosis,
and Fabry's disease. Because oxalate deposition re-
curs rapidly and leads to graft failure, oxalosis prob-
ably is the one condition in which transplantation is
contraindicated in a child. Transplantation in pa-
tients with cystinosis has had variable success, not
because of recurrent cystinosis, but because of re-
jection and other factors that are not well defined.
Increased cystine in the renal interstitium possibly
is carried into the graft via the patient's own mono-
cytes and leukocytes. In patients with Fabry's dis-
ease, transplantation is performed to restore renal
function and to improve nonrenal symptoms. The
results have been poor: of 9 patients studied, 6 died
and only 3 survived with good function [41].
DR. KASSIRER: Dr. Herrin, you mentioned that
transplantation in patients younger than one year is
experimental. What precisely do you mean by that?
DR. HERRIN: A number of children under the age
of one year have received kidney transplants in dif-
ferent centers, but only one child has survived as
long as one year.
DR. KASSIRER: Why are survival rates so low?
DR. HERRIN: I do not have a precise answer, but
technical problems and postoperative infections—
not to mention rejection—seem to be the major
problems currently.
DR. GRUPE: There appear to be technical prob-
lems unique to the infant. Even though micro-
vascular surgery is successful, vessels fail to remain
patent. Relatively large kidneys seem to be associ-
ated with hypertension, hypotension, profuse diure-
sis, and occasionally, inadequate intraabdominal
space. Septicemia is common either because of im-
munosuppression or the immunologic inexperience
of the infant.
DR. BORIS SENIOR (Chief, Pediatric Endocrinolo-
gy and Metabolism, NEMCH): We should consider
one aspect of growth in relation to vitamin D-resis-
tant rickets. The only patients who do grow are the
small fraction treated before the age of one. Appar-
ently these infants can exhibit perfectly normal,
compensatory growth. As Dr. Herrin pointed out,
growth also can be stimulated in patients who have
renal tubular acidosis [42]. If bicarbonate is given
early and vigorously, almost normal growth rates
can obtain. In both instances, there appears to be a
critical time period during which therapy must be
instituted or the opportunity for catch-up growth
will be lost.
DR. KASSIRER: When a kidney from an adult is
transplanted into a child, it appears that hyper-
filtration results immediately but that thereafter the
kidney shrinks and filtration rate returns to normal
for the child's size. I have two questions. First,
does the hyperfiltration have any adverse or salu-
tary effects on salt and water balance, and second,
what is the mechanism of "renal shrinking"?
DR. HERRIN: Hyperfiltration immediately after
transplantation is very helpful in restoring normal
chemical balance. For example, in a 3- or 4-year-old
who produces 8 to 12 liters of urine in 24 hours, the
serum creatinine concentration can fall from ap-
proximately 9.0 to 0.3 mgldl by the next morning. In
such a patient, however, the blood volume has
turned over about 6 to 8 times during the night. As
you point out, it is known that an adult kidney
transplanted into a very small child decreases in
size over 6 to 8 weeks, whereas an infant kidney
transplanted into an adult hypertrophies over the
same period [43]. The mechanism of the com-
pensatory change in kidney size, however, is not
known.
DR. ZELMAN: After the adult kidney shrinks after
the transplant, and provided the patient does not re-
ject the kidneys, does the transplanted kidney then
attain normal size as the patient grows?
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DR. HERRIN: Yes, the new kidney seems to
match function with the patient's size.
DR. COHEN: The patient we are discussing today
was found to have renal insufficiency 10 years ago
at age 4. How would you manage a similar patient of
that age today? Would you recommend trans-
plantation without regard to any metabolic abnor-
malities that might have developed?
DR. HERRIN: Ten years ago we were extremely
reluctant to transplant a kidney into a child under 5
years of age, particularly if the patient was clinically
and chemically stable. At present, I favor early
transplantation in any child over 12 months of age if
growth arrest has been documented, particularly if
a living related donor is available.
DR. KASSIRER: Are there many 10- to 20-year sur-
vivors of kidney transplantation?
DR. HERRIN: Yes. We have several children who
received kidneys 10 to 13 years ago, and the litera-
ture cites more than 30 children who are 10-year
survivors [1, 13, 44].
Reprint requests to Dr. John T. Herrin, Pediatric Nephrology,
Massachusetts General Hospital, Boston, Massachusetts 02114,
U.S.A.
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